BBIO · Company research
BridgeBio Pharma, Inc. Common Stock (BBIO): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
22records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| 4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now | Four biotech companies with advanced drug pipelines present potential investment opportunities as their experimental treatments progress through late-stage development and regulatory review. BridgeBio Pharma has three drug candidates under FDA review with decisions expected through May 2027. Intellia Therapeutics' gene-editing therapy lonvo-z showed 87% reduction in hereditary angioedema attacks. Biogen expects pivotal study results through 2027, while Viking Therapeutics advances obesity treatments in phase III trials. Success depends on regulatory approvals, clinical efficacy, and competitive market positioning. | View source ↗ | Zacks Investment Research | Oct 20, 2026 | bullish | 0.75 | 1 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Oct 14, 2026 | neutral | 0 | 0.6 |
| BridgeBio Pharma, Inc. Actuals & Estimates (BIVA:BBIO) - TradingView | BridgeBio Pharma, Inc. Actuals & Estimates (BIVA:BBIO) TradingView | View source ↗ | TradingView | Oct 14, 2026 | neutral | 0 | 0.6 |
| BridgeBio Pharma (BBIO) Reports Positive Phase 3 Trial Results f - GuruFocus | BridgeBio Pharma (BBIO) Reports Positive Phase 3 Trial Results f GuruFocus | View source ↗ | GuruFocus | Oct 11, 2026 | neutral | 0 | 0.6 |
| BridgeBio Pharma, Inc. (BBIO) Stock Forecasts - Yahoo Finance | BridgeBio Pharma, Inc. (BBIO) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing - The Globe and Mail | FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing The Globe and Mail | View source ↗ | The Globe and Mail | Oct 7, 2026 | neutral | 0 | 0.6 |
| FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing | BridgeBio Pharma announced FDA acceptance of its regulatory filing for infigratinib, an oral drug to treat achondroplasia in children, with priority review and a decision expected by February 4, 2027. The drug demonstrated 2.1 cm/year greater height growth than placebo in Phase III trials. If approved, it would be the first oral therapy for achondroplasia, differentiating it from injectable competitors. BridgeBio also has two other near-term regulatory catalysts (BBP-418 and encaleret) that could diversify its revenue beyond its current marketed product Attruby. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.333 | 1 |
| FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing | BridgeBio Pharma announced FDA acceptance of its regulatory filing for infigratinib, an oral drug to treat achondroplasia in children, with priority review and a decision expected by February 4, 2027. The drug demonstrated 2.1 cm/year greater height growth than placebo in Phase III trials. If approved, it would be the first oral therapy for achondroplasia, differentiating it from injectable competitors. BridgeBio also has two other near-term regulatory catalysts (BBP-418 and encaleret) that could diversify its revenue beyond its current marketed product Attruby. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.333 | 1 |
| New data will show a heart medicine reduced heart-related deaths and hospital stays in women. - Stock Titan | New data will show a heart medicine reduced heart-related deaths and hospital stays in women. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| About 1 in 25 Black Americans carries a gene change linked to a heart condition. Not all develop it. - Stock Titan | About 1 in 25 Black Americans carries a gene change linked to a heart condition. Not all develop it. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| About 1 in 25 Black Americans carries a gene variant linked to heart disease. Education events will span 40 locations. - Stock Titan | About 1 in 25 Black Americans carries a gene variant linked to heart disease. Education events will span 40 locations. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Bridgebio Pharma Stock Price Forecast. Should You Buy BBIO? - StockInvest.us | Bridgebio Pharma Stock Price Forecast. Should You Buy BBIO? StockInvest.us | View source ↗ | StockInvest.us | Oct 2, 2026 | neutral | 0 | 0.6 |
| BridgeBio Pharma, Inc. (BBIO) Stock Forecasts - Yahoo Finance | BridgeBio Pharma, Inc. (BBIO) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 1, 2026 | neutral | 0 | 0.6 |
| Why BridgeBio Pharma (BBIO) Stock Is Down Today - Quiver Quantitative | Why BridgeBio Pharma (BBIO) Stock Is Down Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 23, 2026 | neutral | 0 | 0.6 |
| BridgeBio Pharma (BBIO) Stock Looks Properly Priced For Its Sales Story - Simply Wall Street | BridgeBio Pharma (BBIO) Stock Looks Properly Priced For Its Sales Story Simply Wall Street | View source ↗ | Simply Wall Street | Sep 23, 2026 | neutral | 0 | 0.6 |
| 7 Red Days In A Row: BridgeBio Pharma Stock Is Down 12% - Trefis | 7 Red Days In A Row: BridgeBio Pharma Stock Is Down 12% Trefis | View source ↗ | Trefis | Sep 21, 2026 | neutral | 0 | 0.6 |
| 7 Red Days In A Row: BridgeBio Pharma Stock Is Down 8.8% - Trefis | 7 Red Days In A Row: BridgeBio Pharma Stock Is Down 8.8% Trefis | View source ↗ | Trefis | Aug 31, 2026 | neutral | 0 | 0.6 |
| KKR reportedly assigned almost 60% of BridgeBio stock sale to five firms - Seeking Alpha | KKR reportedly assigned almost 60% of BridgeBio stock sale to five firms Seeking Alpha | View source ↗ | Seeking Alpha | Aug 14, 2026 | neutral | 0 | 0.6 |
| KKR to Sell 5M BridgeBio Shares; Company Receives No Proceeds - Stock Titan | KKR to Sell 5M BridgeBio Shares; Company Receives No Proceeds Stock Titan | View source ↗ | Stock Titan | Aug 14, 2026 | neutral | 0 | 0.6 |
| BridgeBio Pharma (BBIO) Stock Looks Priced At A Premium Despite 148% Returns - Yahoo Finance | BridgeBio Pharma (BBIO) Stock Looks Priced At A Premium Despite 148% Returns Yahoo Finance | View source ↗ | Yahoo Finance | Aug 4, 2026 | neutral | 0 | 0.6 |
| Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead - Zacks Investment Research | Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead Zacks Investment Research | View source ↗ | Zacks Investment Research | Jul 8, 2026 | neutral | 0 | 0.6 |
| Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead - Yahoo Finance | Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead Yahoo Finance | View source ↗ | Yahoo Finance | Jul 8, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.